Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy

References

• Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176. doi:10.1016/S2468-1253(16)30181-928404132
   PubMed Web of Science ®Google Scholar
• AASLD-IDSA Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954. doi:10.1002/hep.2795026111063
   PubMed Web of Science ®Google Scholar
• Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology. 2019;156(2):297–310.30391470
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global health sector strategy on viral hepatitis, 2016–2021. Available from: http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1. Accessed 115, 2016
   Google Scholar
• Edlin BR, Eckhardt BJ, Shu MA, et al. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62:1353–1363. doi:10.1002/hep.2797826171595
   PubMed Web of Science ®Google Scholar
• Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant. 2018;18 Suppl 1:172–253. doi:10.1111/ajt.1455929292603
   PubMed Web of Science ®Google Scholar
• Cotter TG, Paul S, Sandıkçı B, et al. Improved graft survival after liver transplantation for recipients with hepatitis C in the direct‐acting antiviral era. Liver Transpl. 2019. doi:10.1002/lt.25424
   Web of Science ®Google Scholar
• Cotter TG, Paul S, Sandıkçı B, et al. Increasing utilization and excellent initial outcomes following liver transplant of HCV-viremic donors into HCV-negative recipients. Hepatology. 2019. doi:10.1002/hep.30540
   Web of Science ®Google Scholar
• Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810–817. doi:10.1016/j.jhep.2018.06.01029940268
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–327. doi:10.1002/hep.2674424115039
   PubMed Web of Science ®Google Scholar
• Bukh J. The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol. 2016;65:S2–S21. doi:10.1016/j.jhep.2016.07.03527641985
   PubMed Web of Science ®Google Scholar
• Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309:1577–1581. doi:10.1126/science.111332916141076
   PubMed Web of Science ®Google Scholar
• Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41:106–114. doi:10.1002/hep.2051815619235
   PubMed Web of Science ®Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87. doi:10.1002/hep.2725925069599
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57. doi:10.1016/j.jhep.2014.07.02725086286
   PubMed Web of Science ®Google Scholar
• Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61–80. doi:10.1111/j.1478-3231.2011.02540.x21651703
   PubMed Web of Science ®Google Scholar
• Simmonds P. The origin of hepatitis C virus. Curr Top Microbiol Immunol. 2013;369:1–15. doi:10.1007/978-3-642-27340-7_123463195
   PubMed Web of Science ®Google Scholar
• Honda M, Ping LH, Rijnbrand RC, et al. Structural requirements for initiation of translation by internal ribosome entry within genome-length hepatitis C virus RNA. Virology. 1996;222:31–42. doi:10.1006/viro.1996.03958806485
   PubMed Web of Science ®Google Scholar
• von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology. 2007;132:667–678. doi:10.1053/j.gastro.2006.12.00817258731
   PubMed Web of Science ®Google Scholar
• Wolk B, Sansonno D, Krausslich HG, et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol. 2000;74:2293–2304. doi:10.1128/jvi.74.5.2293-2304.200010666260
   PubMed Web of Science ®Google Scholar
• Masaki T, Suzuki R, Murakami K, et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol. 2008;82:7964–7976. doi:10.1128/JVI.00826-0818524832
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416. doi:10.1056/NEJMoa101291221696307
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206. doi:10.1056/NEJMoa101049421449783
   PubMed Web of Science ®Google Scholar
• Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 2015;62:286–293. doi:10.1016/j.jhep.2014.08.05225218788
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403–413. doi:10.1016/S0140-6736(14)60494-324907225
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887. doi:10.1056/NEJMoa121485323607594
   PubMed Web of Science ®Google Scholar
• Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016;64:370–380. doi:10.1002/hep.2846726799692
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150:419–429. doi:10.1053/j.gastro.2015.10.01326497081
   PubMed Web of Science ®Google Scholar
• Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715–725. doi:10.1002/hep.2792226033798
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898. doi:10.1056/NEJMoa140245424725239
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493. doi:10.1056/NEJMoa131636624725238
   PubMed Web of Science ®Google Scholar
• Ahmed A, Felmlee DJ. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses. 2015;7:6716–6729. doi:10.3390/v712296826694454
   PubMed Web of Science ®Google Scholar
• Ogawa E, Furusyo N, Nomura H, et al. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017;52:845–854. doi:10.1007/s00535-016-1290-127913920
   PubMed Web of Science ®Google Scholar
• Akuta N, Sezaki H, Suzuki F, et al. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. J Med Virol. 2017;89:1248–1254. doi:10.1002/jmv.2476728079269
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Ochi H, Hayes CN, et al. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. J Gastroenterol. 2018;53:548–556. doi:10.1007/s00535-017-1380-828815329
   PubMed Web of Science ®Google Scholar
• Lafferty L, Treloar C, Guthrie J, Chambers GM, Butler T. Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison. J Viral Hepat. 2017;24:111–116. doi:10.1111/jvh.1262727778436
   PubMed Web of Science ®Google Scholar
• Abbvie Inc. MAVYRET - full prescribing information. 2018 Available from: https://www.rxabbvie.com/pdf/mavyret_pi.pdf. Accessed 1020, 2018
   Google Scholar
• Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61. doi:10.1128/AAC.02558-16
   Web of Science ®Google Scholar
• Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013;3:514–520. doi:10.1016/j.coviro.2013.06.01423896281
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354–369. doi:10.1056/NEJMoa170241729365309
   PubMed Web of Science ®Google Scholar
• Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417–426. doi:10.1016/j.cgh.2017.09.02728951228
   PubMed Web of Science ®Google Scholar
• Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol. 2017;67:263–271. doi:10.1016/j.jhep.2017.03.03928412293
   PubMed Web of Science ®Google Scholar
• Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062–1068. doi:10.1016/S1473-3099(17)30496-628818546
   PubMed Web of Science ®Google Scholar
• Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389–397. doi:10.1002/hep.2908128128852
   PubMed Web of Science ®Google Scholar
• Poordad F, Pol S, Asatryan A, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018;67:1253–1260. doi:10.1002/hep.2967129152781
   PubMed Web of Science ®Google Scholar
• Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448–1455. doi:10.1056/NEJMoa170405329020583
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis. 2018;67:1010–1017. doi:10.1093/cid/ciy22029566246
   PubMed Web of Science ®Google Scholar
• Reau N, Kwo PY, Rhee S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology. 2018. doi:10.1002/hep.30046
   PubMed Web of Science ®Google Scholar
• Asselah T, Lee SS, Yao BB, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45–51. doi:10.1016/S2468-1253(18)30341-830393106
   PubMed Web of Science ®Google Scholar
• Foster GR, Asselah T, Kopecky-Bromberg S, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019;14:e0208506. doi:10.1371/journal.pone.020850630601818
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2018. doi:10.1016/S0168-8278(18)30351-9
   Web of Science ®Google Scholar
• Flamm S, Mutimer D, Asatryan A, et al. Glecaprevir/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2/3 analysis. J Viral Hepat. 2018. doi:10.1111/jvh.13038
   PubMed Web of Science ®Google Scholar
• Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134–2146. doi:10.1056/NEJMoa161351228564569
   PubMed Web of Science ®Google Scholar
• Osawa M, Imamura M, Teraoka Y, et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol. 2019;54(3):291–296.30334096
   PubMed Web of Science ®Google Scholar
• Uemura H, Uchida Y, Kouyama JI, et al. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol. 2019;54:459–470. doi:10.1007/s00535-018-01543-930612205
   PubMed Web of Science ®Google Scholar
• Krishnan P, Pilot-Matias T, Schnell G, et al. Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials. Antimicrob Agents Chemother. 2018;62. doi:10.1128/AAC.01249-18
   Web of Science ®Google Scholar
• Wyles DWO, Yao B, Reindollar RW, Weilert F, Dufour J-F. Retreatment of hepatitis C virus infection in patients who failed glecaprevir/pibrentasvir. J Hepatol. 2018;68:S623–S624. doi:10.1016/S0168-8278(18)30265-4
   PubMed Web of Science ®Google Scholar
• Dhiman RK, Grover GS, Premkumar M, et al. Direct-acting antiviral therapy is safe and effective in pediatric chronic hepatitis C: the public health perspective. J Pediatr Gastroenterol Nutr. 2019;68:74–80. doi:10.1097/MPG.000000000000213930211847
   PubMed Web of Science ®Google Scholar
• AASLD-IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C; Clin Infect Dis 2018;30;67(10):1477–1492.
   Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511. doi:10.1016/j.jhep.2018.03.02629650333
   PubMed Web of Science ®Google Scholar